Fortress Biotech, Inc. (FBIO)
1.93
-0.06
(-3.02%)
USD |
NASDAQ |
Oct 23, 16:00
1.915
-0.02
(-0.78%)
After-Hours: 20:00
Fortress Biotech Enterprise Value : -37.02M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -37.02M |
| October 22, 2026 | -35.02M |
| October 21, 2026 | -36.69M |
| October 20, 2026 | -36.69M |
| October 19, 2026 | -39.02M |
| October 16, 2026 | -39.02M |
| October 15, 2026 | -37.69M |
| October 14, 2026 | -38.02M |
| October 13, 2026 | -36.35M |
| October 12, 2026 | -31.02M |
| October 09, 2026 | -30.19M |
| October 08, 2026 | -31.69M |
| October 07, 2026 | -33.36M |
| October 06, 2026 | -33.02M |
| October 05, 2026 | -31.69M |
| October 02, 2026 | -33.69M |
| October 01, 2026 | -32.36M |
| September 30, 2026 | -30.03M |
| September 29, 2026 | -28.03M |
| September 28, 2026 | -29.03M |
| September 25, 2026 | -25.36M |
| September 24, 2026 | -25.36M |
| September 23, 2026 | -23.36M |
| September 22, 2026 | -19.70M |
| September 21, 2026 | -21.03M |
| Date | Value |
|---|---|
| September 18, 2026 | -17.70M |
| September 17, 2026 | -17.70M |
| September 16, 2026 | -19.37M |
| September 15, 2026 | -18.37M |
| September 14, 2026 | -17.03M |
| September 11, 2026 | -17.37M |
| September 10, 2026 | -15.70M |
| September 09, 2026 | -13.70M |
| September 08, 2026 | -11.04M |
| September 04, 2026 | -10.71M |
| September 03, 2026 | -11.04M |
| September 02, 2026 | -10.37M |
| September 01, 2026 | -12.04M |
| August 31, 2026 | -10.21M |
| August 28, 2026 | -9.040M |
| August 27, 2026 | -8.040M |
| August 26, 2026 | -7.707M |
| August 25, 2026 | -7.041M |
| August 24, 2026 | -3.710M |
| August 21, 2026 | -5.708M |
| August 20, 2026 | -9.040M |
| August 19, 2026 | -6.375M |
| August 18, 2026 | -4.376M |
| August 17, 2026 | -7.374M |
| August 14, 2026 | -3.710M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 45.20M |
| Kura Oncology, Inc. | 360.28M |
| Spero Therapeutics, Inc. | 15.81M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.602M |
| Revenue (Quarterly) | 18.72M |
| Total Expenses (Quarterly) | 19.19M |
| EPS Diluted (Quarterly) | -0.0779 |
| Gross Profit Margin (Quarterly) | 61.50% |
| Profit Margin (Quarterly) | 3.22% |
| Earnings Yield | 137.6% |
| Normalized Earnings Yield | 126.88 |